Abstract
Biogen Idec is a global research-based company focused on the development,
manufacture and commercialisation of novel therapeutics for human health care.
This new strategic analysis report provides a complete and critical review of
the company and includes unique and independent assessments and forecasts of
key products.
On 12th November 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen
Idec, the world' s third largest biotechnology group. The move was unusual
because, up to now, companies have bought biotechs to generate capital, or
they want a specific product. In contrast, Biogen and IDEC had almost equal
market capitalisations. The merge was instead a move to strengthen pipelines
where both companies faced maturing markets for their main products. The new
group has increased research and development funds to target more potential
compounds. Thanks to its enhanced commercial and manufacturing capabilities,
it should also have more chance of licensing drugs from other companies. In
addition, Biogen Idec should be inherently less risky, with two US$1
billion-plus blockbusters, two recently launched medicines and a deeper and
broader pipeline of potential products.
Biogen Idec is a global research-based company focused on the development,
manufacture and commercialisation of novel therapeutics for human health care.
From its headquarters in Cambridge, MA, and facilities across the globe,
Biogen Idec' s marketed products reach patients in more than 90 countries
worldwide. The company is gaining a reputation as one of the leading
biotechnology innovators, particularly in the fields of cancer and immunology.
The failure of the company to attract a takeover offer from the major
pharmaceutical companies in 2007, means that Biogen Idec will remain an
independent company for the time being. Potential bidders may have been put
off by the escalating share price, or the risky bet on Biogen Idec and Elan' s
multiple sclerosis drug, Tysabri, following its linking to a rare brain
infection that could reduce the drug' s market potential. The successful
re-launch and uptake of Tysabri may go some way to allay these fears, however,
the perceived wisdom within the industry is that we have seen the end of the
so-called ' mega-mergers' and Biogen Idec may have to stand on its own two feet.
Of its key products, Avonex remains the main growth driver alongside Rituxan,
supported by the re-launch of Tysabri for multiple sclerosis (MS).
The group' s core asset is its strong pipeline of middle- to late-stage drugs.
The pipeline contains some promising line-extensions and biologics for
lymphoma, leukaemia and immune disease such as MS, Crohn' s disease and
rheumatoid arthritis. Of particular note are lumiliximab, which could be the
next new medication for chronic lymphocytic leukaemia, galiximab for
non-Hodgkin' s lymphoma, lixivaptan for heart failure, BG-12 for MS and
ocrelizumab, which has the potential to take over from Rituxan in rheumatoid
arthritis as well as being used in combination with Rituxan for MS.
This new strategic analysis report Biogen Idec: Pipeline · Products
· Performance · Potential, provides a complete and critical
review of the company and includes unique and independent assessments and
forecasts of key products. 4D Pharma reports are updated with the latest data
on a continuing basis and the full report is released quarterly. Once a year
the report undergoes a major review in line with the company' s year end.
Buyers of the print/pdf editions will receive the latest version and quarterly
updated reports for a year. Buyers of the web edition receive online access
for one year via an easy-to-use interface with fast navigation and a full text
search facility. All formats are the same price.
View Cart
